Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-042310

Chief Executive Officer sold 15,000 shares at an average $19.27 ($289,026)

  • Chief Executive Officer acquired 15,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kauffman Michael · Chief Executive Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2020-07-10 Exercise or conversion : show line 1 in the form +7,500 $4.75 $35,640 562,622 D
2020-07-10 Sale : show line 2 in the form −7,200 $18.98 $136,627 555,422 D
2020-07-10 Sale : show line 3 in the form −300 $19.71 $5,912 555,122 D
2020-07-09 Exercise or conversion : show line 4 in the form +7,500 $4.75 $35,640 763,989 I
2020-07-09 Sale : show line 5 in the form −7,500 $19.53 $146,487 756,489 I
Open-market sales · 15,000 sh · avg $19.27 · $289,026

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-07-10 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −7,500 $4.75 2023-09-02 7,500 333,561 D
2020-07-09 Exercise or conversion : show line 7 in the form Stock Option (right to buy) −7,500 $4.75 2023-09-02 7,500 377,803 I
Loading xslF345X03/doc4.xml…